Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TransCon TLR7/8 agonist/TransCon IL-2 beta/gamma - Ascendis Pharma

Next Previous
Drug Profile

TransCon TLR7/8 agonist/TransCon IL-2 beta/gamma - Ascendis Pharma

Alternative Names: TransCon TLR7/8 agonist/TransCon IL-2 β/γ - Ascendis Pharma

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascendis Pharma
  • Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Interleukins; Lymphokines; Quinolones; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants; Interleukin 2 receptor agonists; Interleukin receptor common gamma subunit stimulants; Interleukin-2 receptor beta subunit agonists; Regulatory T-lymphocyte stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Apr 2026 No recent reports of development identified for research development in Cancer in Denmark
  • 02 Mar 2022 Early research in Cancer in Denmark (unspecified route)
  • 02 Mar 2022 Ascendis Pharma plans to submit an IND application for TransCon TLR7/8 agnosit and TransCon IL-2 beta/gamma in the fourth quarter of 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top